中国临床药理学杂志2016，Vol.32Issue(6)：483-485,3.DOI:10.13699/j.cnki.1001-6821.2016.06.001
参脉注射液联合左卡尼汀治疗慢性肺源性心脏病合并心力衰竭的临床疗效及安全性评价
Clinical efficacy and safety of levocarnitine combined with Shenmai injection in the treatment of chronic pulmonary heart disease complicated with heart failure
摘要
Abstract
Objective To evaluate the clinical efficacy and safety of le-vocarnitine combined with Shenmai injection in the treatment of chronic pulmonary heart disease complicated with heart failure.Methods A to-tal of 128 patients with chronic pulmonary heart disease complicated with heart failure were randomly divided into treatment group(66 cases) and control group ( 62 cases ).Patients in control group were treated with levocarnitine 3 g, once a day for 3 weeks, while patients in treatment group were treated with Shenmai injection 100 mL, once a day combined with levocarnitine levocarnitine 3 g, once a day for 3 weeks.The clinical efficacy, cardiac function improvement and adverse drug reactions were compared between the two groups.Results After treatment, the total efficacy was 95.45% in the treatment group, significantly higher than 85.48% in the control group ( P <0.05 ).Cardiac functions in two groups after treatment were better than those before treatment, and cardiac function improvement in the treatment group was superior than that in control group ( P<0.05 ).There was no adverse drug reactions.Conclusion Shenmai injection combined with levocarnitine can significantly improve the clinical efficacy of chronic pulmonary heart disease complicated with heart failure with medication safety.关键词
慢性肺源性心脏病/参脉注射液/左卡尼汀/临床疗效/安全性Key words
chronic pulmonary heart disease/levocarnitine/Shenmai injection/heart failure/clinical efficacy/safety分类
医药卫生引用本文复制引用
杨继雷,姚秀叶,谷伟,李彦明,董利平,袁桂莉..参脉注射液联合左卡尼汀治疗慢性肺源性心脏病合并心力衰竭的临床疗效及安全性评价[J].中国临床药理学杂志,2016,32(6):483-485,3.基金项目
河北省张家口市科技局2014年度指导性计划基金资助项目 （）
